NCOA5 is correlated with progression and prognosis in luminal breast cancer

Biochem Biophys Res Commun. 2017 Jan 8;482(2):253-256. doi: 10.1016/j.bbrc.2016.11.051. Epub 2016 Nov 12.

Abstract

Nuclear receptor coactivator 5 (NCOA5) is known to modulate ERα-mediated transcription and has been found to be involved in the progression of several malignancies. However, the potential correlation between NCOA5 and clinical outcome in patients with luminal breast cancer remains unknown. In the present study, we demonstrated that NCOA5 was significantly up-regulated in luminal breast cancer tissues compared with adjacent non-cancerous tissues both in validated cohort and TCGA cohort. Moreover, Kaplan-Meier analysis indicated that patients with high NOCA5 expression had significantly lower overall survival (P = 0.021). Cox regression analysis indicated that the high NOCA5 expression was independent high risk factor as well as old age (>60) and HER-2 expression (P = 0.039; P = 0.003; P = 0.005; respectively). This study provides new insights and evidences that NOCA5 over-expression was significantly correlated with progression and prognosis in luminal breast cancer. However, the precise cellular mechanisms for NOCA5 in luminal breast cancer need to be further explored.

Keywords: Luminal breast cancer; NCOA5; Prognosis.

Publication types

  • Comparative Study

MeSH terms

  • Age Distribution
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / metabolism*
  • Breast Neoplasms / diagnosis
  • Breast Neoplasms / metabolism*
  • Breast Neoplasms / mortality*
  • China / epidemiology
  • Disease Progression
  • Female
  • Humans
  • Incidence
  • Middle Aged
  • Nuclear Receptor Coactivators / metabolism*
  • Prognosis
  • Reproducibility of Results
  • Risk Factors
  • Sensitivity and Specificity
  • Statistics as Topic
  • Survival Rate

Substances

  • Biomarkers, Tumor
  • NCOA5 protein, human
  • Nuclear Receptor Coactivators